AU · rank #6 · 2026-10-22
SENS
NASDAQ · $435M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.388 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | -$0.01 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 5 |
| Insider signal (90d) $125,300 across 1 unique buyers. | 1.337 |
| Analyst upside Consensus target $13.67 | +71.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +47.99% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.88 |
| Gross margin TTM | +54.9% |
| 52w high | $10.64 |
| Market cap (USD) | $435M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Senseonics Holdings develops and commercializes Eversense 365, the only FDA-cleared implantable continuous glucose monitoring system providing up to one year of continuous sensor wear.
Rationale
The 71.5% analyst upside signal is supported by strong Q2 2026 top-line expansion (+120% YoY revenue growth), a management raise to FY2026 guidance ($62M–$66M), and expanding AID integrations with Beta Bionics and Sequel Med Tech.
Material risks
- 1Persistent net losses ($36.7M loss in Q2 2026) and heavy cash burn threaten shareholder value through potential future equity dilution despite recent capital raises.
- 2Established CGM rivals Dexcom and Abbott maintain non-invasive, low-friction wearable workflows and dominant market shares, exposing Senseonics to adoption resistance due to required clinician insertion procedures.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.